Overview

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and other Factor VIII products.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Factor VIII